myo-Inositol trispyrophosphate hexasodium  (Synonyms: ITPP hexasodium)

myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response^[1][2][3].

myo-Inositol trispyrophosphate hexasodium (10 mmol/L; 2 hours) significantly inhibits OCR in all six cell lines (FSaII, SiHa, MDA‐MB‐231, NT2, 9L‐glioma and rhabdomyosarcoma) ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

myo-Inositol trispyrophosphate hexasodium (2 g/kg weekly; IP; 7weeks) sustains its significant effect on life prolongation^[1].
myo-Inositol trispyrophosphate hexasodium (1.5 g/kg weekly; IV; for 8 weeks) remains metastasis-free on pancreatic carcinomas in immunocompetent male Lewis rats weighing 120-150 g with DSL-6A/C1 cells. myo-Inositol trispyrophosphate hexasodium restores the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors^[1].
myo-Inositol trispyrophosphate hexasodium (2 g/kg; once daily for 2 days) shows the most elevated tumour oxygenation at 2 hours in four mouse tumour models (mouse fibrosarcoma FSaII implanted in C3H mice, mouse mammary tumour NT2 in FVb/Nrj mice, human breast cancer MDA‐MB‐231 in NMRI nude mice and human cervix squamous cell carcinoma SiHa in NMRI nude mice) and two rat tumour models (rat 9L‐glioma in Fischer F344 rats and rat rhabdomyosarcoma in WAG/Rij rats)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

737.88

C₆H₆Na₆O₂₁P₆

23103-35-7

Solid

White to off-white

O=P1(O[C@]2([H])[C@@]3([H])[C@@](OP(OP(O3)(O[Na])=O)(O[Na])=O)([H])[C@]4([H])[C@@](OP(OP(O4)(O[Na])=O)(O[Na])=O)([H])[C@@]2([H])OP(O1)(O[Na])=O)O[Na]

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Zahary Raykov, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82.  [Content Brief]

  [2]. Ly-Binh-An Tran, et al. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. J Cell Mol Med. 2019 Mar;23(3):1908-1916.  [Content Brief]

  [3]. Marta Oknińska, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283.  [Content Brief]